Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Journal of Internal Medicine, Volume 300, Issue 5, Page 572-589, November 2026.Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello +3 more
wiley +1 more source
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide. [PDF]
Diabetes Metab Res RevAl Ozairi E +5 more
europepmc +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity. [PDF]
JCEM Case RepLa Vignera S, Condorelli RA.
europepmc +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma. [PDF]
Mater Today BioWang Z +11 more
europepmc +1 more source
Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics
Chemistry – A European Journal, Volume 32, Issue 37, 1 October 2026.A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova +11 more
wiley +1 more source
Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β-cell function. [PDF]
Physiol RepYingyue Q +4 more
europepmc +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.We identified endoplasmic reticulum (ER) stress modulation as a convergent transcription signature across fentanyl and multiple substance use disorder (SUD)‐relevant treatments. Key ER stress genes, including TRIB3, XBP1, and DDIT3, were downregulated, while CEBPB emerged as a shared upstream regulator linked to ER stress–related proteins.
Cheng Zhang, Hu Li, Ming‐Fen Ho
wiley +1 more source
A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia. [PDF]
J Endocr SocLawler HM +9 more
europepmc +1 more source